Rhodiola Rhodiola rosea L.
Also called: arctic root, golden root, rose root, roseroot, king's crown
Rhodiola grows in cold regions and at high altitudes in Europe, Asia and North America, with a long history of use in Russia and Scandinavia. Preparations use the rhizome and root.
- Category
- Botanical
- Part used
- Rhizome and root
- Strongest evidence
- C Limited
- Reviewed
- 2026-10-28
Class 1 Well studied in people. A 2025 meta-analysis (Frontiers in Nutrition) included 26 RCTs (668 healthy adults) of rhodiola for endurance exercise. By their reference titles, 4 combined rhodiola with Cordyceps or Ginkgo and 2 tested isolated salidroside, leaving 20 of rhodiola alone. [4]
Fact-checked 2026-10-28 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
CBrain, mood and sleep2 topics
CSeveral areas, whole body or blood1 topic
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| Any health-related purpose | C | NCCIH states there isn't enough reliable evidence to determine usefulness; most human research is of low-to-moderate quality. [1] |
| Fatigue, stress, endurance and mental performance | C | MSK describes preliminary human data; a systematic review called for better reporting and methodological quality. [2] |
| Mild to moderate depression and generalized anxiety | C | Small studies; in one, rhodiola was better tolerated than sertraline but less effective. [2] |
Main constituents: Salidroside, described as a key constituent [2]
Safety and side effects
- Liver (NIH LiverTox)Nothing found
No published information found in the sources checked.
Details and sources - Pregnancy and breastfeedingEU monograph: safety during pregnancy and lactation has not been established …
2 statements in the profile.
Details and sources - Interactions with medicines8 listed
Losartan; Antidepressants; CYP3A4 substrates; CYP2C9 substrates (e.g. phenytoin, warfarin); P-glycoprotein substrates; Antihypertensives …
Details and sources - Cancer evaluations (IARC, NTP)None found
No IARC or NTP evaluation was found in the lists checked.
Details and sources - FDA new dietary ingredient notifications4 on FDA's list
FDA does not approve dietary supplements. Each entry is one party's filing.
Details and sources - Dose in official monographsStated
EU (EMA HMPC monograph, Revision 1, 20 March 2024), traditional use, adults and elderly: dry extract (DER 1.5-5:1, ethanol 67-70% V/V) single dose …
Details and sources
Interactions
| With | What happens |
|---|---|
| Losartan | Interactions between rhodiola and losartan have been reported. [1] |
| Antidepressants | Rhodiola has MAO-inhibiting activity and may increase serotonergic side effects; clinical relevance not yet determined. [2] |
| Warfarin and phenytoin (CYP2C9 substrates) | Rhodiola modestly inhibits CYP2C9 and may affect narrow-therapeutic-index drugs such as phenytoin and warfarin. [2] |
Tell a pharmacist or doctor about every supplement you take. All documented interactions in this hub.
Regulatory status
- US: herbal products for oral use are often marketed as dietary supplements, which, unlike drugs, are not approved by the FDA before sale; manufacturers are responsible for safety and labeling. [1]
- EU: an EU herbal monograph covers traditional use (long-standing use, not clinical trials) for temporary relief of stress symptoms such as fatigue, in adults, for no more than two weeks without medical advice. [3]
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
US status
What FDA's published records show. FDA does not approve dietary supplements.
- FDA's published NDI notification list has 4 entries naming Rhodiola rosea (earliest NDI 983 submitted 2017-01-30; most recent NDI 1459 submitted 2026-01-20). Each entry is one party's notification; the list gives the date of FDA's response letter but not what it said. [P1]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
Liver (NIH LiverTox)
- No published information found in the sources checked.
Interactions with medicines
- Losartan: Interactions between rhodiola and losartan have been reported. [P7]
- Antidepressants: Rhodiola has MAO-inhibiting activity and may increase serotonergic side effects (clinical relevance yet to be determined); MSK also notes that concurrent use with prescription antidepressants was reported to cause tachyarrhythmia. [P6]
- CYP3A4 substrates: Preclinical studies suggest rhodiola inhibits CYP3A4 and can affect the intracellular concentration of drugs metabolized by this enzyme; clinical relevance is yet to be determined. [P6]
- CYP2C9 substrates (e.g. phenytoin, warfarin): Rhodiola modestly inhibits CYP2C9 and may affect drugs metabolized by this enzyme, particularly those with a narrow therapeutic index. [P6]
- P-glycoprotein substrates: In preclinical studies, rhodiola was shown to inhibit P-gp activity and can interfere with the metabolism of certain drugs; clinical relevance is not established. [P6]
- Antihypertensives: May increase hypotensive side effects; clinical relevance is not yet determined. [P6]
- CNS stimulants: May enhance the hypertensive effect; clinical relevance is not yet determined. [P6]
- Medicinal products in general (EU monograph): EU herbal monograph section 4.5: no clinically relevant interactions have been observed. [P5]
Alcohol
- No published information found in the sources checked.
Interactions with other herbs and supplements
- No published information found in the sources checked.
Adulteration and substitution
- Booker et al. 2016 (Phytomedicine) analyzed about 40 commercial products by HPTLC, mass spectrometry and 1H NMR: about one fifth of products claiming R. rosea contained no rosavin, some appeared to lack salidroside, and about 80% of the remainder were lower in rosavin than registered products and appeared adulterated with other Rhodiola species; Rhodiola crenulata is believed to be a common adulterant. [P8]
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity test or examination of each dietary-ingredient component — 21 CFR 111.75(a)(1)(i) requires at least one appropriate test or examination to verify the identity of any component that is a dietary ingredient, unless FDA grants a petition-based exemption under 111.75(a)(1)(ii). [P4]
- Rosavin (and salidroside) marker profile by HPTLC, MS or 1H NMR — Booker et al. 2016: rosavin is the key reference marker distinguishing R. rosea from related species, and substitution with other Rhodiola species was common in tested products. [P8]
Supply and conservation
- No published information found in the sources checked.
Absorption in people
- No published information found in the sources checked.
Formulations studied to change absorption
Human data only.
- No published information found in the sources checked.
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- EU (EMA HMPC monograph, Revision 1, 20 March 2024), traditional use, adults and elderly: dry extract (DER 1.5-5:1, ethanol 67-70% V/V) single dose 144-200 mg, 1-2 times daily, daily dose 144-400 mg; not recommended under 18 years; consult a doctor if symptoms persist longer than 2 weeks. [P5]
Pregnancy and breastfeeding
- EU monograph: safety during pregnancy and lactation has not been established; in the absence of sufficient data, use during pregnancy and lactation is not recommended. No fertility data available. [P5]
- NCCIH: little is known about whether it is safe to use rhodiola during pregnancy or while breastfeeding. [P7]
Sources for this profile
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- IARC Monographs. List of Classifications (list last updated 2026-07-23 per page data; checked 2026-10-29), 2026-07-23. monographs.iarc.who.int
- National Toxicology Program (NIEHS). Technical Reports list (checked 2026-10-29), 2026-10-29. ntp.niehs.nih.gov
- eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (up to date as of 10/23/2026), 2026-10-23. ecfr.gov
- European Medicines Agency, HMPC. European Union herbal monograph on Rhodiola rosea L., rhizoma et radix, EMA/HMPC/24177/2023, Final - Revision 1 (20 March 2024), 2024-03-20. ema.europa.eu
- Memorial Sloan Kettering Cancer Center. About Herbs: Rhodiola (Last Updated April 16, 2026), 2026-04-16. mskcc.org
- NCCIH. Rhodiola: Usefulness and Safety (Last Updated: April 2025), 2025-04. nccih.nih.gov
- Booker A, et al. The authenticity and quality of Rhodiola rosea products. Phytomedicine 2016;23(7):754-62 (PMID 26626192), 2016-06-15. pubmed.ncbi.nlm.nih.gov
Sources
- NCCIH. Rhodiola: Usefulness and Safety (Last Updated: 2025-04), 2025-04. nccih.nih.gov
- Memorial Sloan Kettering Cancer Center. About Herbs: Rhodiola (Last Updated 2026-04-16), 2026-04-16. mskcc.org
- European Medicines Agency, HMPC. Rhodiolae roseae rhizoma et radix (arctic root) - herbal medicinal product, 2014-06-16. ema.europa.eu
- Wang X, et al. The effect of Rhodiola rosea supplementation on endurance performance and related biomarkers: a systematic review and meta-analysis. Front Nutr 2025;12:1645346 (PMID 41080184), 2025-09-25. pubmed.ncbi.nlm.nih.gov
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in botanical: Aloe vera · American ginseng · Amla · Andrographis · Arjuna · Arnica · Aronia (black chokeberry) · Asafoetida · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.